Literature DB >> 14733590

A comparative study of different presentation strategies for an HIV peptide immunogen.

Luis J Cruz1, Enrique Iglesias, Julio C Aguilar, Luis J González, Osvaldo Reyes, Fernando Albericio, David Andreu.   

Abstract

Different strategies have been used to increase the immunogenicity of an antigenic HIV peptide as a vaccine candidate. The selected B-cell epitope comprises 15 amino acids (317-331) of the V3 region of HIV-1, JY1 isolate (subtype D), in tandem with a T-helper epitope corresponding to the 830-844 region of tetanus toxoid. Several presentations, including oligomerization, multiple antigenic peptide dendrimers, and conjugation to dextran beads or to other macromolecular carriers, have been synthesized and evaluated. Murine sera from the different presentations of the V3 epitope have been compared with regard to antibody titers and cross-reactivity with heterologous HIV subtypes. The dendrimer version of the peptide conjugated to HBsAg protein was a better immunogen than the dendrimer alone and showed a higher immunogenicity than other multimeric presentations or than the peptide alone conjugated to dextran. The dendrimer version, either alone or conjugated to HBSAg, enhanced cross-reactivity toward heterologous V3 sequences relative to monomeric peptide. In addition, fine epitope mapping of the entire JY1 sequence by sera from the different immunization groups was performed by the spot synthesis technique. Results showed that the amino acids involved in molecular recognition were LXQXXY or LXQXLY, with particularly strong recognition of the C-terminal region LGQALY. However, cross-reactivity toward the heterologous sequences did not completely correlate with recognition of particular amino acids in the primary sequences. These results can find application in the development of HIV vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14733590     DOI: 10.1021/bc034119j

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  5 in total

1.  Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.

Authors:  Maxim Totrov; Xunqing Jiang; Xiang-Peng Kong; Sandra Cohen; Chavdar Krachmarov; Aidy Salomon; Constance Williams; Michael S Seaman; Ruben Abagyan; Timothy Cardozo; Miroslaw K Gorny; Shixia Wang; Shan Lu; Abraham Pinter; Susan Zolla-Pazner
Journal:  Virology       Date:  2010-07-21       Impact factor: 3.616

2.  MAP dendrimer elicits antibodies for detecting rat and mouse GH-binding proteins.

Authors:  Roberto M Aguilar; Frank J Talamantes; Juan J Bustamante; Jesus Muñoz; Lisa R Treviño; Andrew O Martinez; Luis S Haro
Journal:  J Pept Sci       Date:  2009-02       Impact factor: 1.905

3.  Location of immunization and interferon-γ are central to induction of salivary gland dysfunction in Ro60 peptide immunized model of Sjögren's syndrome.

Authors:  Hongen Yin; Jelle L Vosters; Nienke Roescher; Anil D'Souza; Biji T Kurien; Paul P Tak; John A Chiorini
Journal:  PLoS One       Date:  2011-03-28       Impact factor: 3.240

4.  Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells.

Authors:  Juan Pablo Jaworski; Shelly J Krebs; Maria Trovato; Dina N Kovarik; Zachary Brower; William F Sutton; Garrett Waagmeester; Rossella Sartorius; Luciana D'Apice; Antonella Caivano; Nicole A Doria-Rose; Delphine Malherbe; David C Montefiori; Susan Barnett; Piergiuseppe De Berardinis; Nancy L Haigwood
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

5.  Dendrimeric nanoarchitectures mediated transdermal and oral delivery of bioactives.

Authors:  V Gajbhiye; P Vijayaraj Kumar; A Sharma; A Agarwal; A Asthana; N K Jain
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.